GPT and metabolic dysfunction-associated steatotic liver disease: Zheng et al. [49] evaluated the diagnostic performance of a combined and sequential strategy including GP73 levels and CK18-M30 fragments to predict MASH in MASLD patients with persistently normal ALT levels.